Thanks to the new technology, early detection with accuracy of Alzheimer's is now possible which can lead to better outcomes through timely interventions
Alzheimer's disease is one of the most challenging neurological disorders, affecting millions globally. It is characterised by progressive memory loss, cognitive decline, and behavioural changes. While the disease is often associated with older adults, the importance of detecting it in its early stages cannot be overstated. Early detection allows for timely intervention, which can slow down the progression of the disease, offering patients more years of quality life. Moreover, early diagnosis empowers individuals and their families to plan for the future, make informed decisions, and access the latest treatments.
One of the key advantages of early detection is the ability to begin treatment when the brain is still relatively healthy. Current medications, while not a cure, work best when started early. They can help manage symptoms like memory loss and confusion. Additionally, lifestyle changes such as regular exercise, cognitive therapy, and a healthy diet can have a more significant impact when implemented during the early stages of Alzheimer's.
Researchers are now focused on identifying the disease's biomarkers before significant memory problems arise, providing a window of opportunity for early intervention. Beyond medical benefits, early detection has psychological and social advantages. It allows patients to maintain independence for a longer period, reduces anxiety associated with uncertainty, and provides clarity to families about caregiving responsibilities. Detecting Alzheimer's in its early stages has become a critical aspect of managing the disease effectively. With the advent of advanced diagnostic tools like CLEIA, early detection is now more achievable than ever.
Agappe Diagnostics in collaboration with Fujirebio Holdings of Japan, has made a groundbreaking advancement in India's healthcare sector by introducing Chemiluminescent Enzyme Immunoassay (CLEIA) technology. This development is a monumental step forward in the indigenous manufacturing of cutting-edge diagnostic tools, specifically designed for early detection of critical diseases like Alzheimer's, Cancer, and Gastrointestinal disorders.
“We have long standing productive relations with India that are all set to further strengthen and flourish,” said Takashi Ariyoshi, deputy chief of Japanese embassy in India.
CLEIA, an evolved version of the widely recognized Chemiluminescent Immunoassay (CLIA), merges the sensitivity of chemiluminescence detection with the precision of enzyme immunoassays. This powerful combination allows for the accurate detection of low concentrations of biomarkers, making it a game-changer in early diagnosis. In the case of Alzheimer's, early identification of disease-specific biomarkers can significantly slow down cognitive decline by enabling timely interventions, including medications and lifestyle changes.
In modern In-Vitro Diagnostics (IVD), CLEIA plays a crucial role not just in early detection but also in disease progression monitoring and guiding personalized treatment.
These aspects are particularly relevant in Alzheimer's care, where early diagnosis opens the door to medical treatments and cognitive therapies that can prolong independence and improve quality of life.
This technology is a significant leap in advancing immunoassay technology in India. Through this partnership, cartridge-based CLEIA systems have been developed and launched, supporting the healthcare system with advanced, locally manufactured diagnostic tools.
Besides, beyond Alzheimer's, CLEIA is instrumental in detecting cancer markers at an early stage, significantly improving survival rates for patients. The Inod- Japanese partnership underlines the benefits of the "Make in India" initiative, reducing dependency on imports in critical healthcare technologies.
(The writer is a senior journalist; views are personal)
